Brief: Vaccinex Says Phase 1/2 Trial OF Pepinemab In Alzheimer's Disease To Enrol Patients In Sept
14/08/2020 13:53
Aug 14 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND
PROVIDES CORPORATE UPDATE
* VACCINEX INC - PHASE 1/2 TRIAL OF PEPINEMAB IN ALZHEIMER'S
DISEASE TO BEGIN ENROLLING PATIENTS IN SEPTEMBER
* VACCINEX INC - ON TRACK TO REPORT POTENTIALLY PIVOTAL
PHASE 2
HUNTINGTON'S DISEASE TOPLINE DATA BY EARLY OCTOBER
* VACCINEX INC - CASH AND CASH EQUIVALENTS AND MARKETABLE
SECURITIES ON JUNE 30, 2020 WERE $0.5 MILLION
Source text for Eikon: ID:nGNX6PDqKl
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease